Crispr Therapeutics AG (CRSP) is near the top in its industry group according to InvestorsObserver. CRSP gets an overall rating of 51. That means it scores higher than 51 percent of stocks. Crispr Therapeutics AG gets a 70 rank in the Biotechnology industry. Biotechnology is number 99 out of 148 industries.
Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.
What do These Ratings Mean?
Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 51 means the stock is more attractive than 51 percent of stocks.
These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.
What's Happening With Crispr Therapeutics AG Stock Today?
Crispr Therapeutics AG (CRSP) stock is trading at $54.42 as of 1:06 PM on Tuesday, Nov 12, a rise of $3.51, or 6.89% from the previous closing price of $50.91. The stock has traded between $51.26 and $56.16 so far today. Volume today is more active than usual. So far 1,053,858 shares have traded compared to average volume of 652,735 shares.
